Literature DB >> 11821816

Micrometastasis in the bone marrow of patients with lung cancer associated with a reduced expression of E-cadherin and beta-catenin: risk assessment by immunohistochemistry.

Kenji Sugio1, Shinichiro Kase, Takashi Sakada, Koji Yamazaki, Masafumi Yamaguchi, Kaoru Ondo, Tokujiro Yano.   

Abstract

BACKGROUND: The presence of disseminated tumor cells in bone marrow is considered to be a premetastatic state, which is called micrometastasis. To evaluate the relationship between micrometastasis and cellular adhesion molecules in the primary lesion, E-cadherin and beta-catenin were immunohistochemically investigated. Methods. Fifty-eight patients with non-small cell lung cancer who underwent a complete resection were entered into this study. Tumor cells in bone marrow aspirates were detected by immunohistochemistry using cytokeratin (CK) 18. Immunohistochemical studies of E-cadherin and beta-catenin were performed in the corresponding primary tumor.
RESULTS: CK-positive cells were detected in the bone marrow aspirates from 27 of 58 patients. A reduced expression of the E-cadherin and beta-catenin was found in 16 (27.6%) and in 22 (37.9%) of 58 patients, respectively. In 26 cases with a reduced expression of E-cadherin and/or beta-catenin, 16 cases had CK-positive cells, whereas 11 of 32 cases with normal expression of both factors had CK-positive cells (P=.0392). The patients with micrometastasis demonstrated an earlier recurrence (P =.0642) and a significantly poorer survival (P =.0437) than those without such cells.
CONCLUSIONS: Micrometastasis in the bone marrow might be a significant predictor of poor prognosis, and a reduced expression of E-cadherin and beta-catenin are important determinants for the metastatic capability of individual cancer cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11821816     DOI: 10.1067/msy.2002.119793

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  8 in total

1.  [Long-term survival of personalized surgical treatment of locally advanced non-small cell lung cancer based on molecular staging].

Authors:  Qinghua Zhou; Yingkang Shi; Jun Chen; Bin Liu; Yun Wang; Daxing Zhu; Hong-Tao Zhang; Peng Xu; Youling Gong; Gang Chen; Sen Wei; Xiaoming Qiu; Zhongxi Niu; Xiaofeng Chen; Zhe Lei; Liang Duan; Zhu Wu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-02

2.  Analysis of tumor-derived DNA in plasma and bone marrow fluid in lung cancer patients.

Authors:  Taichiro Goto; Yosuke Hirotsu; Toshio Oyama; Kenji Amemiya; Masao Omata
Journal:  Med Oncol       Date:  2016-02-20       Impact factor: 3.064

3.  Expression of e-cadherin and beta-catenin in human esophageal squamous cell carcinoma: relationships with prognosis.

Authors:  Xi-Jiang Zhao; Hui Li; Hua Chen; Yan-Xue Liu; Li-Hua Zhang; Su-Xiang Liu; Qing-Lai Feng
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

Review 4.  Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer.

Authors:  Sumitra Mohan; Francesca Chemi; Ged Brady
Journal:  Transl Lung Cancer Res       Date:  2017-08

Review 5.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

6.  Why victory in the war on cancer remains elusive: biomedical hypotheses and mathematical models.

Authors:  Leonid Hanin
Journal:  Cancers (Basel)       Date:  2011-01-17       Impact factor: 6.639

7.  Effects of Surgery and Chemotherapy on Metastatic Progression of Prostate Cancer: Evidence from the Natural History of the Disease Reconstructed through Mathematical Modeling.

Authors:  Leonid Hanin; Marco Zaider
Journal:  Cancers (Basel)       Date:  2011-09-20       Impact factor: 6.639

8.  Clinical significance of disseminated tumour cells in non-small cell lung cancer.

Authors:  A K Rud; E Borgen; G M Mælandsmo; K Flatmark; H Le; D Josefsen; I Solvoll; C B Schirmer; Å Helland; L Jørgensen; O T Brustugun; Ø Fodstad; K Boye
Journal:  Br J Cancer       Date:  2013-08-13       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.